Digital health market intelligence
Galen Growth actively tracks digital health investment, innovation, partnerships, and evidence—combining a decade of market history with current research and analysis.
Latest annual report
Sixth annual edition
The sixth annual Index benchmarks 24 pharmaceutical companies across digital health strategy and the strength of their recent partner portfolios.
Explore our intelligence
Published reports on funding, ecosystems, innovation, evidence, and market development.
02Editorial analysis of the events, companies, and strategic shifts shaping digital health.
03The annual evidence-led selection of promising early-stage digital health ventures.
04Static practical resources for market evaluation, diligence, and healthcare innovation.
Latest insight
Pharma’s partnerships with digital health ventures fell 21% in the first nine months of 2026, yet deals with obesity care-delivery ventures hit a record nine, because GLP-1 drugs only pay off if patients stay on them.
Read the analysisResearch library
Presented by Galen Growth at Health Revolution Congress 2026 in Barcelona, this presentation explores how Health Management Solutions are becoming the operating layer of modern healthcare as AI adoption, investment and enterprise-scale deployment accelerate.
M&A now accounts for 95% of digital health exits as the IPO window stays shut to all but the most evidence-led ventures. Galen Growth's Digital Health Exits 2026 report — powered by HealthTech Alpha — analyses 282 exits from 2025 to June 2026 and the Roche/PathAI deal that turns vendor neutrality into a board-level governance question.